Sanjiv S. Agarwala

机构：Temple University · ORCID：0000-0001-9416-8768

发表论文 306 篇 · 总被引 28282 次 · h-index 65

代表论文

• Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial (2024 · The Lancet Oncology · 被引 223)
• Systemic Therapy for Melanoma: ASCO Guideline Update (2023 · Journal of Clinical Oncology · 被引 214)
• Efficacy and Safety of Autologous Dendritic Cell–Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer (2022 · JAMA Oncology · 被引 93)
• Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma (2023 · Cancer Chemotherapy and Pharmacology · 被引 44)
• Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101) (2022 · Clinical Cancer Research · 被引 19)
• Systemic Therapy for Melanoma: ASCO Guideline Update Q and A (2023 · JCO Oncology Practice · 被引 18)